Zika Virus Vaccines by Company Profile, Deals Type, Funding, Clinical Trials Insight, Regulatory Landscape & Recent Development

It is predicted that Zika virus vaccines shot will available to the public by 2018.

Zika virus is an emerging viral disease that is transmitted through the bite of an infected mosquito, primarily Aedes aegypti, the same vector that transmits chikungunya, dengue and yellow fever. Zika has a similar epidemiology, clinical presentation and transmission cycle in urban environments as chikungunya and dengue, although it generally causes milder illness.

The highest risk is to pregnant women due to the connection the virus has with serious birth defects.  Pregnant women who contract the virus have a high possibility of giving birth to a baby with microcephaly, a neurodevelopment disorder, where a baby is born with an unusually small head due to abnormal brain development in the womb or after birth.  Complications of this disorder include seizures and developmental issues.

Due to the serious nature of global risk, the WHO has declared the microcephaly cases associated with the Zika virus a Public Health Emergency of International Concern (PHEIC).  With no vaccines or cure the virus and its risks are expected to continue to spread.  The WHO is predicting up to 4 Million Zika cases in the Americas by 2016 and the World Bank is projecting the short-term economic impact for 2016, in Latin America and the Caribbean to be about US$3.5 Billion.

With fears of Zika virus reaching new heights,Zika virus vaccines are gaining popularity. Many Government agencies and research institutes support pharmaceutical companies for the development & manufacturing of Zika virus vaccines. It is predicted that Zika virus vaccines shot will available to the public by 2018.

The research report presents a comprehensivestudy of the Zika virus vaccines with details. It provides essential insights of introduction of Zika virus, current situation and areas with Zika virus and funding in Zika virus vaccines research. Additionally, the report includes assessment of clinical trials and regulatory landscape of Zika virus vaccines development. Key trends in terms of partnerships, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the Zika virus vaccines development such as Sanofi Pasteur,ImmunoVaccines Inc, Inovio Pharmaceuticals, Inc, Valneva, Bharat Biotech International Pvt. Ltd., NewLink Genetics. The major players are evaluated on various parameters such as company overview, product outlook and Zika virus vaccines latest development and trends.

This 87 Page report has been analyzed from 7 viewpoints: 

1.    Zika Virus – Introduction, Signs and Symptoms, Transmission, Diagnosis, Treatment & Prevention

2.    Current Situation & Areas with Zika Virus

3.    Competitive Landscape of The Zika Virus Vaccines Companies

4.    Funding in Zika Virus Vaccines Research

5.    Zika Virus Vaccines – Clinical Trials Insight by Phase & Trial Status

6.    Zika Virus Vaccines – Regulatory Landscape

7.    Key Companies Analysis

 

Research Methodology

DPI Research’s team of researchers and analysts use a variety of research sources for making a report. Most of the data – information and statistics for our products is gathered using the secondary research by in–house team of researchers. The main objective of DPI Research’s secondary research exercise is to exhaust all sources of published information including websites of government agencies, consumer and trade associations, annual reports and accounts of companies, news articles from well–known publications and online databases like Factiva, OneSource, Thomson, Hoovers, etc. The data thus gathered is send to our team of analysts who verify that data and look for research gaps. These gaps are filled through primary research, that is, our analysts gain information from various agencies, associations and companies using customer surveys, telephonic and email interviews, etc. Finally, all the information collected using secondary and primary research is analysed and synthesized by our analysts and is presented in a report.

Industry information and data for this report has been sourced through numerous channels including publicly available information from companies’ and industry association websites. For industry sizing, segmentation and trends, apart from desk research, we have contacted industry experts and executives from various companies.

Market forecasts are done using statistical forecasting techniques based on historic performance. Statistical tools are further supplemented with qualitative parameters like industry expectation, economic drivers, new product development, customer surveys, ongoing research, etc.

All the information gathered was then analysed and synthesized by in–house team of analysts.

Europe Influenza Vaccines Market Size, Development and Forecasts

Influenza Vaccine Market is expected to reach more than US$ 1 Billion across the 5 major markets (5MM) of the France, Germany, Italy, Spain and United Kingdom by the year end of 2022.
Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against Influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries.
United Kingdom influenza vaccine market is the most attractive of those covered in the report. The United Kingdom market for influenza vaccine is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. Germany will be the second–largest market for influenza vaccine which is expected to grow at a CAGR of XX% by 2022. France is expected to be third largest influenza vaccine market being followed by Italy by the end of the forecasted period.
Further, prudent analysis has been done on the competitor’s part, where three major players grab major share of the influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into influenza vaccine sales forecast for the top five countries, comprising the UK, France, Italy, Spain and Germany until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players
in the influenza vaccine market, such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of influenza vaccine market.
Five Major European Markets (5MM) covered in the report are as follows:
United Kingdom
France
Italy
Spain
Germany
Major and Promising Vaccines covered in the report are as follows:
Fluzone High–Dose
Fluzone Quadrivalent
Intradermal (ID) Trivalent
Vaxigrip
Fluarix Quadrivalent
Flulaval Quadrivalent
Fluenz Tetra
FluMist Quadrivalent
Flublok
VN–100
M–001
VAX–2012Q
TAK – 850
Flucelvax Quadrivalent
Afluria Quadrivalent
Agrippal
Fluad
Fluvirin
Fluvax
Key Companies Covered in the Report are as follows:
Sanofi Pasteur
GlaxoSmithKline(GSK)
Seqirus
AstraZenecca
Protein Sciences Corporation
Novavax
Daiichi–Sankyo
Mitsubishi Tanabe Pharma
BiondVax Pharmaceuticals Ltd
VaxInnate

DPI Research Published a New Report on Influenza Vaccines Market in Top 5 European Countries to 2022

Influenza Vaccine Market is expected to reach more than US$ 1 Billion across the 5 major markets (5MM) of the France, Germany, Italy, Spain and United Kingdom by the year end of 2022.
Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against Influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries.
United Kingdom influenza vaccine market is the most attractive of those covered in the report. The United Kingdom market for influenza vaccine is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. Germany will be the second–largest market for influenza vaccine which is expected to grow at a CAGR of XX% by 2022. France is expected to be third largest influenza vaccine market being followed by Italy by the end of the forecasted period.
Further, prudent analysis has been done on the competitor’s part, where three major players grab major share of the influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into influenza vaccine sales forecast for the top five countries, comprising the UK, France, Italy, Spain and Germany until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players
in the influenza vaccine market, such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of influenza vaccine market.
Five Major European Markets (5MM) covered in the report are as follows:
United Kingdom
France
Italy
Spain
Germany
Major and Promising Vaccines covered in the report are as follows:
Fluzone High–Dose
Fluzone Quadrivalent
Intradermal (ID) Trivalent
Vaxigrip
Fluarix Quadrivalent
Flulaval Quadrivalent
Fluenz Tetra
FluMist Quadrivalent
Flublok
VN–100
M–001
VAX–2012Q
TAK – 850
Flucelvax Quadrivalent
Afluria Quadrivalent
Agrippal
Fluad
Fluvirin
Fluvax
Key Companies Covered in the Report are as follows:
Sanofi Pasteur
GlaxoSmithKline(GSK)
Seqirus
AstraZenecca
Protein Sciences Corporation
Novavax
Daiichi–Sankyo
Mitsubishi Tanabe Pharma
BiondVax Pharmaceuticals Ltd
VaxInnate

DPI Research Published a New Report on Influenza Vaccines Market in Top 5 European Countries to 2022

Influenza Vaccine Market is expected to reach more than US$ 1 Billion across the 5 major markets (5MM) of the France, Germany, Italy, Spain and United Kingdom by the year end of 2022.
Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against Influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries.
United Kingdom influenza vaccine market is the most attractive of those covered in the report. The United Kingdom market for influenza vaccine is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. Germany will be the second–largest market for influenza vaccine which is expected to grow at a CAGR of XX% by 2022. France is expected to be third largest influenza vaccine market being followed by Italy by the end of the forecasted period.
Further, prudent analysis has been done on the competitor’s part, where three major players grab major share of the influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into influenza vaccine sales forecast for the top five countries, comprising the UK, France, Italy, Spain and Germany until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players
in the influenza vaccine market, such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of influenza vaccine market.
Five Major European Markets (5MM) covered in the report are as follows:
United Kingdom
France
Italy
Spain
Germany
Major and Promising Vaccines covered in the report are as follows:
Fluzone High–Dose
Fluzone Quadrivalent
Intradermal (ID) Trivalent
Vaxigrip
Fluarix Quadrivalent
Flulaval Quadrivalent
Fluenz Tetra
FluMist Quadrivalent
Flublok
VN–100
M–001
VAX–2012Q
TAK – 850
Flucelvax Quadrivalent
Afluria Quadrivalent
Agrippal
Fluad
Fluvirin
Fluvax
Key Companies Covered in the Report are as follows:
Sanofi Pasteur
GlaxoSmithKline(GSK)
Seqirus
AstraZenecca
Protein Sciences Corporation
Novavax
Daiichi–Sankyo
Mitsubishi Tanabe Pharma
BiondVax Pharmaceuticals Ltd
VaxInnate

Influenza Vaccines Market in Top 5 European Countries to 2022 – Market Size, Development and Forecasts

Influenza Vaccine Market is expected to reach more than US$ 1 Billion across the 5 major markets (5MM) of the France, Germany, Italy, Spain and United Kingdom by the year end of 2022.
Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against Influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries.
United Kingdom influenza vaccine market is the most attractive of those covered in the report. The United Kingdom market for influenza vaccine is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. Germany will be the second–largest market for influenza vaccine which is expected to grow at a CAGR of XX% by 2022. France is expected to be third largest influenza vaccine market being followed by Italy by the end of the forecasted period.
Further, prudent analysis has been done on the competitor’s part, where three major players grab major share of the influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into influenza vaccine sales forecast for the top five countries, comprising the UK, France, Italy, Spain and Germany until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players
in the influenza vaccine market, such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of influenza vaccine market.
Five Major European Markets (5MM) covered in the report are as follows:
United Kingdom
France
Italy
Spain
Germany
Major and Promising Vaccines covered in the report are as follows:
Fluzone High–Dose
Fluzone Quadrivalent
Intradermal (ID) Trivalent
Vaxigrip
Fluarix Quadrivalent
Flulaval Quadrivalent
Fluenz Tetra
FluMist Quadrivalent
Flublok
VN–100
M–001
VAX–2012Q
TAK – 850
Flucelvax Quadrivalent
Afluria Quadrivalent
Agrippal
Fluad
Fluvirin
Fluvax
Key Companies Covered in the Report are as follows:
Sanofi Pasteur
GlaxoSmithKline(GSK)
Seqirus
AstraZenecca
Protein Sciences Corporation
Novavax
Daiichi–Sankyo
Mitsubishi Tanabe Pharma
BiondVax Pharmaceuticals Ltd
VaxInnate

United States Influenza Vaccine Market

United States Influenza Vaccine Market is expected to reach more than US$ 2.5 Billion by the year end of 2022.
Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccine and introduction of quadrivalent influenza vaccine.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It provides essential insights into United States influenza vaccine market and forecast. It covers vaccination pattern, doses distribution, production and offers a clear view of the regulatory landscape. Additionally, the report includes insight of clinical trials, pipeline and promising vaccines in United States influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.
The report concludes with the profiles of major players in the influenza vaccine market such as Sanofi Pasteur, GSK, Seqirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. The report also entails major drivers and barriers of influenza vaccine market.
Major and Promising Vaccine covered in the report are as follows:
1. Fluzone High–Dose
2. Fluzone Quadrivalent
3. Intradermal (ID) Trivalent
4.Vaxigrip
5. Fluarix Quadrivalent
6. Flulaval Quadrivalent
7. Fluenz Tetra
8.FluMist Quadrivalent
9. Flublok
10. VN–100
11. M–001
12. VAX–2012Q
13. TAK – 850
14. Flucelvax Quadrivalent
15. Afluria Quadrivalent
16. Agrippal
17. Fluad
18. Fluvirin
19. Fluvax
Key Companies Covered in the Report are as follows
1. Sanofi Pasteur
2. GlaxoSmithKline(GSK)
3. Seqirus
4. AstraZenecca
5. Protein Sciences Corporation
6. Novavax
7. Daiichi–Sankyo
8. Mitsubishi Tanabe Pharma
9. BiondVax Pharmaceuticals Ltd
10. VaxInnate

United States Influenza Vaccine Market is expected to reach more than US$ 2.5 Billion by the year end of 2022

United States Influenza Vaccine Market is expected to reach more than US$ 2.5 Billion by the year end of 2022.
Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccine and introduction of quadrivalent influenza vaccine.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It provides essential insights into United States influenza vaccine market and forecast. It covers vaccination pattern, doses distribution, production and offers a clear view of the regulatory landscape. Additionally, the report includes insight of clinical trials, pipeline and promising vaccines in United States influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.
The report concludes with the profiles of major players in the influenza vaccine market such as Sanofi Pasteur, GSK, Seqirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. The report also entails major drivers and barriers of influenza vaccine market.
Major and Promising Vaccine covered in the report are as follows:
1. Fluzone High–Dose
2. Fluzone Quadrivalent
3. Intradermal (ID) Trivalent
4.Vaxigrip
5. Fluarix Quadrivalent
6. Flulaval Quadrivalent
7. Fluenz Tetra
8.FluMist Quadrivalent
9. Flublok
10. VN–100
11. M–001
12. VAX–2012Q
13. TAK – 850
14. Flucelvax Quadrivalent
15. Afluria Quadrivalent
16. Agrippal
17. Fluad
18. Fluvirin
19. Fluvax
Key Companies Covered in the Report are as follows
1. Sanofi Pasteur
2. GlaxoSmithKline(GSK)
3. Seqirus
4. AstraZenecca
5. Protein Sciences Corporation
6. Novavax
7. Daiichi–Sankyo
8. Mitsubishi Tanabe Pharma
9. BiondVax Pharmaceuticals Ltd
10. VaxInnate
Research Methodology 
DPI Research’s team of researchers and analysts use a variety of research sources for making a report. Most of the data – information and statistics – for our products is gathered using the secondary research by in–house team of researchers. The main objective of DPI Research’s secondary research exercise is to exhaust all sources of published information including websites of government agencies, consumer and trade associations, annual reports and accounts of companies, news articles from well–known publications and online databases like Factiva, OneSource, Thomson, Hoovers, etc. The data thus gathered is send to our team of analysts who verify that data and look for research gaps. These gaps are filled through primary research, that is, our analysts gain information from various agencies, associations and companies using customer surveys, telephonic and email interviews, etc. Finally, all the information collected using secondary and primary research is analysed and synthesized by our analysts and is presented in a report.
Industry information and data for this report has been sourced through numerous channels including publically available information from companies’ and industry association websites. For industry sizing, segmentation and trends, apart from desk research, we have contacted industry experts and executives from various companies.
Market forecasts are done using statistical forecasting techniques based on historic performance. Statistical tools are further supplemented with qualitative parameters like industry expectation, economic drivers, new product development, customer surveys, ongoing research, etc.
All the information gathered was then analysed and synthesized by in–house team of analysts.

United States Influenza Vaccine Market, Vaccination Analysis, Distribution, Production, Pipeline Insights, Clinical Trials, Deals Type, Regulatory, Price Trends, Competitive Strategies and Forecast,2016 to 2022

United States Influenza Vaccine Market is expected to reach more than US$ 2.5 Billion by the year end of 2022.
Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against influenza vaccine and introduction of quadrivalent influenza vaccine.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It provides essential insights into United States influenza vaccine market and forecast. It covers vaccination pattern, doses distribution, production and offers a clear view of the regulatory landscape. Additionally, the report includes insight of clinical trials, pipeline and promising vaccines in United States influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details.
The report concludes with the profiles of major players in the influenza vaccine market such as Sanofi Pasteur, GSK, Seqirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of influenza vaccine market from 2011 to 2022. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period. The report also entails major drivers and barriers of influenza vaccine market.
Major and Promising Vaccine covered in the report are as follows:
1. Fluzone High–Dose
2. Fluzone Quadrivalent
3. Intradermal (ID) Trivalent
4.Vaxigrip
5. Fluarix Quadrivalent
6. Flulaval Quadrivalent
7. Fluenz Tetra
8.FluMist Quadrivalent
9. Flublok
10. VN–100
11. M–001
12. VAX–2012Q
13. TAK – 850
14. Flucelvax Quadrivalent
15. Afluria Quadrivalent
16. Agrippal
17. Fluad
18. Fluvirin
19. Fluvax
Key Companies Covered in the Report are as follows
1. Sanofi Pasteur
2. GlaxoSmithKline(GSK)
3. Seqirus
4. AstraZenecca
5. Protein Sciences Corporation
6. Novavax
7. Daiichi–Sankyo
8. Mitsubishi Tanabe Pharma
9. BiondVax Pharmaceuticals Ltd
10. VaxInnate
Research Methodology 
DPI Research’s team of researchers and analysts use a variety of research sources for making a report. Most of the data – information and statistics – for our products is gathered using the secondary research by in–house team of researchers. The main objective of DPI Research’s secondary research exercise is to exhaust all sources of published information including websites of government agencies, consumer and trade associations, annual reports and accounts of companies, news articles from well–known publications and online databases like Factiva, OneSource, Thomson, Hoovers, etc. The data thus gathered is send to our team of analysts who verify that data and look for research gaps. These gaps are filled through primary research, that is, our analysts gain information from various agencies, associations and companies using customer surveys, telephonic and email interviews, etc. Finally, all the information collected using secondary and primary research is analysed and synthesized by our analysts and is presented in a report.
Industry information and data for this report has been sourced through numerous channels including publically available information from companies’ and industry association websites. For industry sizing, segmentation and trends, apart from desk research, we have contacted industry experts and executives from various companies.
Market forecasts are done using statistical forecasting techniques based on historic performance. Statistical tools are further supplemented with qualitative parameters like industry expectation, economic drivers, new product development, customer surveys, ongoing research, etc.
All the information gathered was then analysed and synthesized by in–house team of analysts.

Global Influenza Vaccines Market and Forecast to 2021 – Size, Share, Growth and Trends Analysis

Seasonal Influenza Vaccine Market is expected to reach more than US$ 4 Billion across the seven major markets (7MM) of the United States, France, Germany, Italy, Spain, United Kingdom and Japan by the year end of 2022.

Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against seasonal influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries. The barriers limiting the growth of the influenza market include limited patient awareness regarding the threat of influenza and the importance of influenza vaccinations, high investment and strict regulations act as barriers for new entrants.

The United States seasonal influenza vaccine market is the most attractive of those covered in the report. The United States market for seasonal influenza vaccine is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. United Kingdom will be the second–largest market for seasonal influenza vaccine which is expected to grow at a CAGR of XX% by 2022. Germany is expected to be third largest seasonal influenza vaccine market being followed by Japan by the end of the forecasted period.

Further, prudent analysis has been done on the competitor’s part, where three major players grab major share of the seasonal influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the seasonal influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into seasonal influenza vaccine sales forecasts for the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in seasonal influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the seasonal influenza vaccine market such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook, and sales analysis of seasonal influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of seasonal influenza vaccine market.

Seven Major Markets(7MM) covered in the report are as follows:

1.    United States

2.    United Kingdom

3.    France

4.    Italy

5.    Spain

6.    Germany

7.    Japan

Major and Promising Vaccines covered in the report are as follows:

1.    Fluzone High–Dose

2.    Fluzone Quadrivalent

3.    Intradermal (ID) Trivalent

4.    Vaxigrip

5.    Fluarix Quadrivalent

6.    Flulaval Quadrivalent

7.    Fluenz Tetra

8.    FluMist Quadrivalent

9.    Flublok

10.VN–100

11.M–001

12.VAX–2012Q

13.TAK – 850

14.Flucelvax Quadrivalent

15.Afluria Quadrivalent

16.Agrippal

17.Fluad

18.Fluvirin

19.Fluvax

Seasonal Influenza Vaccine Report is segmented with 10 Chapters:

Chapter 1: Chapter one is the introduction with Executive Summary

Chapter 2: Chapter two provides overall recent and forecasts data for the seasonal influenza vaccine market in the top seven countries. This Chapter divided into 4 parts

1.    Overall seasonal influenza vaccine market data from 2010 to 2022

2.    Overall number of persons vaccinated with seasonal influenza vaccine data from 2010 to 2022

3.    Seasonal influenza vaccine market share in the top seven countries data from 2010 to 2022

4.    Persons being vaccinated with influenza vaccine share in the top seven countries data from 2010 to 2022

Chapter 3: Key market drivers and barriers in the seasonal influenza vaccine market.

Chapter 4:Chapter four gives detailed recent and forecasts for the seasonal influenza vaccine markets in the US, the UK, France, Italy, Spain, Germany and Japan, comprising of market size, total number of persons vaccinated, number of children vaccinated, number of 60+ years of age persons vaccinated, number of pregnant women vaccinated, number of chronic medical condition persons vaccinated, number of healthcare workers vaccinated and vaccination coverage.

Chapter 5: Chapter five gives detailed information on seasonal influenza vaccine production & distribution in United States. The information includes vaccine choices remain available for patients, providers, prices of a dose of vaccine, production, supply, and allocation by the major seasonal influenza vaccine manufacturers, seasonal influenza vaccine distribution & demand, seasonal influenza vaccine effectiveness, managing influenza with diagnostic resources, distribution method of seasonal influenza vaccination.

Chapter 6: Chapter six offers information about regulatory landscape including the approval process and an overview of the regulatory authorities in the United States, EU and Japan.

Chapter 7: Chapter seven highlights key M&A deals that took place in the seasonal influenza vaccine market between 2003 and 2015 and lists the major collaborations, licensing, exclusive and distribution agreements deals.

Chapter 8: Chapter eight provides detailed pipeline influenza vaccines in various companies’ pipelines with clinical development and early stage development vaccines.

Chapter 9: Chapter nine offers detailed information of the recruiting clinical trials statement by phase, trial status, study sponsor name and study phase.

Chapter 10: Chapter ten gives information on the key players in the market with business overview, product outlook and sales analysis of the seasonal influenza vaccine.

 

DPI Research publish a new report on “Global Influenza Vaccines Market and Forecast to 2021 – Size, Share, Growth and Trends Analysis”

Seasonal Influenza Vaccine Market is expected to reach more than US$ 4 Billion across the seven major markets (7MM) of the United States, France, Germany, Italy, Spain, United Kingdom and Japan by the year end of 2022.

Market growth can be attributed to factors such as increased disease awareness, expanded recommendations by governmental and advisory bodies to be vaccinated against seasonal influenza, introduction of quadrivalent influenza vaccines, increase in the size of the elderly population in most countries. The barriers limiting the growth of the influenza market include limited patient awareness regarding the threat of influenza and the importance of influenza vaccinations, high investment and strict regulations act as barriers for new entrants.

The United States seasonal influenza vaccine market is the most attractive of those covered in the report. The United States market for seasonal influenza vaccine is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. United Kingdom will be the second–largest market for seasonal influenza vaccine which is expected to grow at a CAGR of XX% by 2022. Germany is expected to be third largest seasonal influenza vaccine market being followed by Japan by the end of the forecasted period.

Further, prudent analysis has been done on the competitor’s part, where three major players grab major share of the seasonal influenza vaccine market by revenue. Sanofi Pasteur, GlaxoSmithKline(GSK), Seqirus, AstraZeneca and Protein Sciences Corporation are the key influencers with their products in the seasonal influenza vaccine market. Other emerging players such as Novavax, Daiichi–Sankyo, Mitsubishi Tanabe Pharma, BiondVax Pharmaceuticals Ltd, and VaxInnate are making novel technology based influenza vaccine which is likely to affect the market share during the forecast period.

The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projection using a suitable set of assumptions and methodologies. It provides essential insights into seasonal influenza vaccine sales forecasts for the top seven countries, comprising the US, the UK, France, Italy, Spain, Germany and Japan until 2022. It also covers vaccination patterns and geographic distribution and offers a clear view of the regulatory landscape. Additionally, the report includes assessment of clinical trials, pipeline and promising vaccines in seasonal influenza vaccine market. Key trends in terms of M&A, collaborations and licensing agreements are analyzed with details. The report concludes with the profiles of major players in the seasonal influenza vaccine market such as Sanofi Pasteur, GSK, Sequirus, AstraZenecca and Protein Sciences Corporation. The major market players are evaluated on various parameters such as company overview, product outlook, and sales analysis of seasonal influenza vaccine market from 2011 to 2022. The report also entails major drivers and barriers of seasonal influenza vaccine market.

Seven Major Markets(7MM) covered in the report are as follows:

1.    United States

2.    United Kingdom

3.    France

4.    Italy

5.    Spain

6.    Germany

7.    Japan

Major and Promising Vaccines covered in the report are as follows:

1.    Fluzone High–Dose

2.    Fluzone Quadrivalent

3.    Intradermal (ID) Trivalent

4.    Vaxigrip

5.    Fluarix Quadrivalent

6.    Flulaval Quadrivalent

7.    Fluenz Tetra

8.    FluMist Quadrivalent

9.    Flublok

10.VN–100

11.M–001

12.VAX–2012Q

13.TAK – 850

14.Flucelvax Quadrivalent

15.Afluria Quadrivalent

16.Agrippal

17.Fluad

18.Fluvirin

19.Fluvax

Seasonal Influenza Vaccine Report is segmented with 10 Chapters:

Chapter 1: Chapter one is the introduction with Executive Summary

Chapter 2: Chapter two provides overall recent and forecasts data for the seasonal influenza vaccine market in the top seven countries. This Chapter divided into 4 parts

1.    Overall seasonal influenza vaccine market data from 2010 to 2022

2.    Overall number of persons vaccinated with seasonal influenza vaccine data from 2010 to 2022

3.    Seasonal influenza vaccine market share in the top seven countries data from 2010 to 2022

4.    Persons being vaccinated with influenza vaccine share in the top seven countries data from 2010 to 2022

Chapter 3: Key market drivers and barriers in the seasonal influenza vaccine market.

Chapter 4:Chapter four gives detailed recent and forecasts for the seasonal influenza vaccine markets in the US, the UK, France, Italy, Spain, Germany and Japan, comprising of market size, total number of persons vaccinated, number of children vaccinated, number of 60+ years of age persons vaccinated, number of pregnant women vaccinated, number of chronic medical condition persons vaccinated, number of healthcare workers vaccinated and vaccination coverage.

Chapter 5: Chapter five gives detailed information on seasonal influenza vaccine production & distribution in United States. The information includes vaccine choices remain available for patients, providers, prices of a dose of vaccine, production, supply, and allocation by the major seasonal influenza vaccine manufacturers, seasonal influenza vaccine distribution & demand, seasonal influenza vaccine effectiveness, managing influenza with diagnostic resources, distribution method of seasonal influenza vaccination.

Chapter 6: Chapter six offers information about regulatory landscape including the approval process and an overview of the regulatory authorities in the United States, EU and Japan.

Chapter 7: Chapter seven highlights key M&A deals that took place in the seasonal influenza vaccine market between 2003 and 2015 and lists the major collaborations, licensing, exclusive and distribution agreements deals.

Chapter 8: Chapter eight provides detailed pipeline influenza vaccines in various companies’ pipelines with clinical development and early stage development vaccines.

Chapter 9: Chapter nine offers detailed information of the recruiting clinical trials statement by phase, trial status, study sponsor name and study phase.

Chapter 10: Chapter ten gives information on the key players in the market with business overview, product outlook and sales analysis of the seasonal influenza vaccine.